HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Ursula Schmidt-Erfurth Selected Research

ranibizumab (Lucentis)

1/2016Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD.
8/2014Impact of vitreomacular adhesion on ranibizumab mono- and combination therapy for neovascular age-related macular degeneration.
5/2014Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
5/2014Refractive changes after pharmacologic resolution of diabetic macular edema.
12/2013Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration.
10/2013Therapeutic interventions for macular diseases show characteristic effects on near and distance visual function.
6/2013Response of retinal sensitivity to ranibizumab treatment of macular edema after acute branch retinal vein occlusion.
2/2013Correlation of OCT characteristics and retinal sensitivity in neovascular age-related macular degeneration in the course of monthly ranibizumab treatment.
12/2012Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
5/2012Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Ursula Schmidt-Erfurth Research Topics

Disease

57Macular Degeneration (Age-Related Maculopathy)
01/2016 - 09/2002
26Macular Edema
10/2015 - 01/2009
25Choroidal Neovascularization
12/2013 - 03/2002
11Diabetic Retinopathy (Retinopathy, Diabetic)
10/2015 - 01/2005
7Geographic Atrophy
12/2015 - 04/2010
6Epiretinal Membrane (Epiretinal Membranes)
11/2015 - 10/2010
6Cataract (Cataracts)
10/2015 - 01/2010
5Cysts
10/2015 - 12/2010
5Edema
12/2014 - 04/2003
5Melanoma (Melanoma, Malignant)
08/2013 - 09/2002
4Retinal Detachment (Retinal Detachments)
08/2015 - 06/2007
4Atrophy
06/2015 - 05/2011
4Retinal Vein Occlusion
06/2013 - 03/2009
3Multiple Sclerosis
01/2015 - 01/2010
3Uveitis
04/2014 - 10/2013
3Scotoma (Scintillating Scotoma)
10/2013 - 01/2003
3Neoplasms (Cancer)
08/2013 - 01/2010
3Inflammation
09/2012 - 06/2011
2Ganglion Cysts (Ganglion)
10/2015 - 06/2014
2Retinopathy of Prematurity (Retrolental Fibroplasia)
09/2015 - 01/2015
2Disease Progression
05/2014 - 01/2005
2Eye Diseases (Eye Disease)
11/2013 - 03/2012
2Cicatrix (Scar)
10/2012 - 04/2010
2Optic Nerve Injuries
09/2012 - 08/2011
2Papilledema
11/2011 - 04/2010
2Central Serous Chorioretinopathy
08/2009 - 04/2003
2Hemorrhage
05/2009 - 12/2007
2Retinal Perforations
07/2007 - 11/2006
2Back Pain (Backache)
02/2004 - 10/2002
1Albinism
11/2014
1Vitreous Detachment (Posterior Vitreous Detachment)
08/2014
1Capsule Opacification
06/2014
1Dizziness (Lightheadedness)
04/2014
1Eye Pain
01/2014
1Pathologic Neovascularization
11/2013
1Pathologic Processes
11/2013
1Type 2 Diabetes Mellitus (MODY)
04/2013
1Burns
10/2012
1Hyperemia
08/2012
1Eye Hemorrhage
08/2012
1Pain (Aches)
08/2012
1Heart Failure
08/2012
1Nausea
08/2012
1Hypertension (High Blood Pressure)
08/2012
1Optic Neuritis (Retrobulbar Neuritis)
08/2011

Drug/Important Bio-Agent (IBA)

45Retinaldehyde (Retinal)IBA
01/2016 - 04/2003
21ranibizumab (Lucentis)FDA Link
01/2016 - 12/2007
21verteporfin (Visudyne)FDA Link
08/2014 - 09/2002
14Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2014 - 05/2008
12bevacizumabFDA Link
05/2014 - 10/2006
11afliberceptIBA
10/2015 - 09/2011
101-phenyl-3,3-dimethyltriazene (PDT)IBA
08/2014 - 03/2002
9Fluorescein (Funduscein)FDA LinkGeneric
08/2013 - 04/2003
6Triamcinolone (Aristocort)FDA Link
05/2014 - 01/2006
3CytokinesIBA
08/2015 - 03/2009
3Triamcinolone Acetonide (Azmacort)FDA LinkGeneric
10/2013 - 04/2006
3Indocyanine Green (Cardio-Green)FDA LinkGeneric
02/2013 - 04/2003
2ROPIBA
09/2015 - 01/2015
2ChemokinesIBA
08/2015 - 07/2012
2CholesterolIBA
12/2014 - 01/2005
2N-acetyltryptophanamide (NATA)IBA
08/2014 - 09/2012
2Uveal melanomaIBA
07/2012 - 12/2007
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
12/2009 - 03/2009
1tandospironeIBA
12/2015
12,4- diamino- 5- cyclohexyl- 6- methylpyrimidineIBA
10/2015
1Multifocal choroiditisIBA
02/2015
1corrigendumIBA
01/2015
1Twin twin transfusion syndromeIBA
01/2015
1Hemoglobins (Hemoglobin)IBA
12/2014
1Melanins (Melanin)IBA
11/2014
1salicylhydroxamic acid (SHAM)IBA
11/2014
1PhospholipidsIBA
11/2013
1Dihydrotachysterol (AT 10)IBA
08/2013
1First StepIBA
10/2012
1Interleukin-6 (Interleukin 6)IBA
07/2012
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
07/2012
1InterleukinsIBA
07/2012
1flt3 ligand protein (flt3 ligand)IBA
07/2012
1Interleukin-7 (Interleukin 7)IBA
07/2012
1Chemokine CCL5IBA
07/2012
1InterferonsIBA
07/2012
1Interleukin-8 (Interleukin 8)IBA
07/2012
1Platelet-Derived Growth FactorIBA
07/2012
1Coloring Agents (Dyes)IBA
06/2012
1LuteinIBA
10/2011
1carbamide peroxide (E.R.O.)IBA
05/2011
1Biological Markers (Surrogate Marker)IBA
01/2011
1poly(dG-dA)n.poly(dC-dT)n (((GA)n))IBA
04/2010

Therapy/Procedure

17Photochemotherapy (Photodynamic Therapy)
08/2014 - 03/2002
16Lasers (Laser)
10/2015 - 01/2003
8Light Coagulation
10/2015 - 03/2010
5Injections
08/2014 - 01/2010
4Retreatment
09/2012 - 12/2005
3Intravitreal Injections
11/2015 - 12/2007
3Vitrectomy
08/2015 - 10/2010
2Radiotherapy
08/2013 - 08/2013
1Intraocular Lenses (Intraocular Lens)
06/2014
1Particle Accelerators
08/2013
1Traction
07/2012
1Off-Label Use
01/2010